Abstract

GOOD CLINICAL RESULTS with testosterone propionate in the treatment of functional uterine bleeding have been reported from several clinics during the past 3 years (1-9). It has, however, been found by a number of investigators that the administration of this hormone resulted in the appearance of arrhenomimetic phenomena (hirsuties, hoarseness, enlargement of the clitoris) (3, 8-11). Our studies have shown that these unpleasant side-effects occur infrequently if the therapeutic dose does not exceed 300 mg. per month and if certain precautions are taken in selection of cases and the hormone administration is controlled with vaginal smears (11, 12). However, the necessity for employing these pre’ cautions detracts somewhat from the value of this form of therapy. For this reason, we attempted to find some other androgen which might possess the therapeutic properties of testosterone propionate without inducing arrhenomimetic effects. During the course of of this investigation, the endocrinologic properties of a number of compounds related structurally to testosterone have been studied.

This content is only available as a PDF.
You do not currently have access to this article.